March 4, 2019 News by BioNews Staff #ACTRIMS2019 ā Jeffrey Cohen, MD, is New President of ACTRIMS Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and ResearchĀ at the Cleveland Clinic, is the newly named Ā president of ACTRIMS, the Americas Committee for Treatment and Research in Multiple Sclerosis. Cohen’s appointment concluded the 2019 ACTRIMS ForumĀ that ran…
October 16, 2018 News by BioNews Staff #ECTRIMS2018 – MS PATHS Just Starting to See Potential, Aims for Remission as Treatment Goal, Biogen Exec Says MS PATHS, a way of capturing data on disease progression and treatment response in thousands of multiple sclerosis (MS) patients being treated at any of 10 participating clinics, has among its goals that of making clinical remission ā a prolonged absence of any disease activity ā possible, said an…
October 15, 2018 News by BioNews Staff #ECTRIMS2018 – Post-hoc Analyses Support Safety and Efficacy of Mavenclad, Merck KGaA Says Substantial data supporting both the effectiveness and safety of Mavenclad (cladribine tablets) is before the U.S. Food and Drug Administration (FDA), and may lead to its approval as a short-course oral treatment for people with relapsing-remitting multiple sclerosis (RRMS) some seven years after a first such request…
October 15, 2018 News by BioNews Staff #ECTRIMS2018 ā As Siponimod Awaits FDA Decision, Mouse Work Helps in Understanding Benefits Seen in SPMS Mouse studies ofĀ siponimod ā a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and EU ā were among presentations given by NovartisĀ at the 34th European Committee for Treatment and Research in Multiple SclerosisĀ (ECTRIMS), held Oct. 10-12 in Berlin. Animal work might seem…
October 12, 2018 News by BioNews Staff #ECTRIMS2018 – From Sun to Salt: Growing Role of Environment in MS A person’s genes influence the development of multiple sclerosis (MS), but so does the environment ā both that in which an MS patient lives, and that which a patient creates through diet and other lifestyle choices, researchers said in a Thursday session at the 34th congress of the European…
October 11, 2018 News by BioNews Staff #ECTRIMS2018 ā Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity Data from two European trials ā a real-life study in Italy, and a long-term Czech trial looking at impact on cognition ā supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who…
October 4, 2018 News by BioNews Staff #ECTRIMS2018 – Emerging MS Treatments, from Cannabinoids to Diet, Among Highlights at Conference Thousands of scientists, doctors, pharmaceutical company executives and others ā representing about 100 countries ā will meet for three days to discuss and debate the latest developments in multiple sclerosis (MS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, best known as…
October 31, 2017 News by BioNews Staff #MSParis2017 ā Advances in Progressive and Pediatric MS Top ECTRIMS Highlights, NMSS Says A giant leap in research and interest in progressive multiple sclerosis ā from a few people pushing for such work to 2,000 listening to updates on it ā a successful first trial in children, and a growing body of potentially safer treatments for relapsing MS were among the highlights of…
October 31, 2017 News by BioNews Staff #MSParis2017 ā Ocrevus Trial Data May Lead to Key Biomarkers of Chronic Inflammation, Genentech Says Potential new ways of capturing disease progression in multiple sclerosis (MS) patients ā including those with chronic as opposed to active inflammation ā are coming to the fore as analyses continue into the huge amounts of data collected during pivotal clinical trials that led to Ocrevus’ approval, a leadingĀ GenentechĀ researcher…
October 27, 2017 News by BioNews Staff #MSParis2017 ā Lemtrada Shows Good Safety and Lasting Efficacy Over 7 Years, Doctor Says in Interview Lemtrada (alemtuzumab) remains a “game-changer” of a treatment for relapsing multiple sclerosis (MS), with benefits continuing and no new side effects seen in a study of its use that now goes out seven years, Aaron Boster, a neuroimmunologist at Ohio Health, said in an interview atĀ the…
October 27, 2017 News by BioNews Staff #MSParis2017 ā Potential Progressive MS Treatment on Move in US and Europe, MedDay CEO Says This is a special edition of Multiple Sclerosis News Today's daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway in Paris, France. The MS News today team in on-site at the conference, providing exclusive coverage of the presentations and speakers.
May 26, 2016 News by BioNews Staff MS Australia Puts Out an Owner’s Manual for ‘MS Bike’ and Anyone Willing to Take It for a Spin A bicycle specially designed to mimic the symptoms of multiple sclerosis (MS) now has its own owner’s manual, and the group behind the bike’s creation is inviting anyone interested to build their own experience of the spasticity and physical discomforts so well-known to people with the disease. The manual, which…
May 2, 2016 News by BioNews Staff #CMSC16 – An Interview with Dr. Fred Lublin of the Center for Multiple Sclerosis at Mount Sinai Dr. Fred Lublin, a neuroimmunologist with a specialty in experimental therapies, will open this year’s annual meeting of the Consortium of Multiple Sclerosis Centers on June 1 with an address questioning the continuing importance of relapses in multiple sclerosis (MS). But the question raised by the title of the…
April 18, 2016 News by BioNews Staff #CMSC16 – An Interview with June Halper, the Consortium’s CEO and an MS Nurse Practitioner When the 2016 annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) opens June 1, marking the organization’s 30th anniversary, at its head will be its executive director, June Halper. The honor is fitting. Halper, a nurse practitioner with a specialty in multiple sclerosis (MS) since 1978, has…
February 18, 2016 News by BioNews Staff FDA Grants ‘Breakthrough Therapy’ Designation to Genentechās Ocrelizumab for PPMS Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment forĀ primary progressive multiple sclerosis (PPMS),Ā Breakthrough Therapy DesignationĀ based on positiveĀ Phase 3 clinical trial results showing thatĀ ocrelizumab significantly reduced disability progression and other disease activity markers compared toĀ placebo. The FDA designation is…
January 18, 2016 News by BioNews Staff Bike With Multiple Sclerosis Symptoms Debuts for 2016 Australia Fundraising Race One of the teams participating in the 10th anniversary of the MS Melbourne Cycle,Ā an annual biking challenge to raise money for MS Australia,Ā has built a bicycle that as closely as possible replicatesĀ theĀ physical difficulties and discomforts that typify multiple sclerosis (MS). AĀ collaboration between the companyĀ Grey Australia, paralympic athlete Carol…
December 3, 2015 by BioNews Staff Coral Gables, FL MS Exchange Event This Saturday To Explore Relapsing MS Management An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease.Ā The Coral Gables MS Exchange eventĀ will be held from 10:30 a.m. to 2:15 p.m. on…
October 10, 2015 News by BioNews Staff Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015 https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3 Read theĀ articles mentioned in theĀ podcast: #ECTRIMS2015 ā Another Attendee Record #ECTRIMS2015 ā āVitamin D plays important role in MS inflammation.ā ā Jorge Correale #ECTRIMS2015 ā āWhen you stop smoking you can decrease the risk of disease progression.ā ā Jorge Correale Discovering a New World in…
June 16, 2015 News by BioNews Staff FDA Taps Online Patient Database To Gain Access To Patient-Reported MS Health Data In an effort to access firsthand patient data as a means of improving healthcare and drug safety, the Food and Drug Administration (FDA) hasĀ announced a unique partnership withĀ Ā PatientsLikeMe, an online network of 350,000 patients who have reported on their own personal experiences in living with over 2,500 different diseases. The…
October 15, 2014 News by BioNews Staff Spasticity Drug to be Tested on Multiple Sclerosis Patients in Early 2015 Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity ā a chronic condition associated with patients with brain disorders, including Multiple Sclerosis —Ā at the next American Neurological Associationās Annual Meeting in Baltimore, Maryland. The Phase 1 randomized,…
August 11, 2014 News by BioNews Staff Higher Body Temperature in RRMS Patients Could Cause Increased Fatigue Researchers have recently discovered that the fatigue that patients withĀ multiple sclerosisĀ (MS) experience is not the same kind of fatigue that healthy people feel from time to time, nor is it caused by the same factors. The National Multiple Sclerosis SocietyĀ reports that around 80% of people who suffer from…
August 10, 2014 News by BioNews Staff JCV Virus May Be Missed in Patients Who Take Popular MS Drug, According To Study Multiple sclerosisĀ (MS) patients who are prescribedĀ TysabriĀ have an increased risk to develop the rare, often fatal infection of the brain called progressive multifocal leukoencephalopathy (PML), according to a recent study. PML is caused by a common virus that infects blood cells and can be mobilized by popular RRMS drug Natalizumab,…
May 30, 2014 News by BioNews Staff MS Views & News Awards Questcor With “Recognition of Appreciation” Award Multiple Sclerosis Advocacy Questcor Pharmaceuticals, Inc. is a drug development company with a viable Multiple Sclerosis drug called H.P. ActharĀ® Gel, which is currently approved in the U.S. by the FDA for the treatment of acute exacerbations of multiple sclerosis in adults. However, in addition to developing and commercializing MS therapies, the…
May 2, 2014 by BioNews Staff New Multiple Sclerosis Drug Target of U.S. and Japanese Researchers The National Center of Neurology and Psychiatry,Ā based in Japan, announced that they willĀ initiateĀ a 3-month clinical trial on 9 patients withĀ multiple sclerosis,Ā beginning inĀ March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…
May 2, 2014 News by BioNews Staff Benefits of Cognitive Reserve in Multiple Sclerosis May Also Benefit TBI Patients Researchers from theĀ Kessler FoundationĀ have found that higher educational achievement reduces the negative impact ofĀ traumatic brain injuryĀ (TBI) on cognitive status. The study appeared inĀ Archives of Physical Medicine & Rehabilitation. It was reported in the study that cognitiveĀ ability after experiencing TBI differs in individuals even when their injury levelsĀ were comparable. As…